Revolution Medicines announced on April 13, 2026, positive topline results from the Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) patients.12
Daraxonrasib achieved median overall survival (OS) of 13.2 months vs. 6.7 months for standard chemotherapy (hazard ratio 0.40, p < 0.0001), nearly doubling survival time.1234
The trial met primary endpoints of OS and progression-free survival (PFS), plus key secondary endpoints, in the intent-to-treat population including RAS-mutated and non-mutated patients.12
Daraxonrasib was well tolerated with a manageable safety profile and no new safety signals.12
Company plans regulatory submissions including FDA New Drug Application using a National Priority Voucher; data to be presented at 2026 ASCO meeting.123
Stock rose nearly 40% following the announcement.3
Sources:
1. https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit
2. https://www.fiercebiotech.com/biotech/revolutions-much-hyped-ras-inhibitor-hits-key-survival-goals-phase-3-pancreatic-cancer
3. https://www.biospace.com/drug-development/revolution-rises-40-as-pancreatic-cancer-drug-doubles-survival
4. https://www.stocktitan.net/news/RVMD/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-0gvppuunntx4.html